Anavex Life Sciences Corp. announced the successful development of a once-daily oral tablet formulation for the ANAVEX®3-71 program. This new modified-release oral tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, enabling once-daily dosing.
This achievement was confirmed in a Phase 1b clinical trial (ANAVEX3-71-002), which evaluated the pharmacokinetics and safety of both immediate- and modified-release formulations in healthy male and female adults. The study successfully achieved its primary endpoint, demonstrating safety and tolerability consistent with prior ANAVEX®3-71 studies.
The company believes that this preferred modified-release formulation will allow it to advance a competitive molecule into future studies. The goal is to address the present and persistent medical needs of people living with schizophrenia and neurodegenerative disorders, enhancing patient convenience and compliance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.